Found: 23
Select item for more details and to access through your institution.
Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia.
- Published in:
- Pharmacology Research & Perspectives, 2024, v. 12, n. 2, p. 1, doi. 10.1002/prp2.1191
- By:
- Publication type:
- Article
In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT<sub>1A</sub> Receptor Agonist for the Treatment of Schizophrenia.
- Published in:
- Pharmaceutical Research, 2022, v. 39, n. 5, p. 837, doi. 10.1007/s11095-022-03267-1
- By:
- Publication type:
- Article
First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica.
- Published in:
- PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0125034
- By:
- Publication type:
- Article
Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: A conference report<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2001, v. 69, n. 6, p. 387, doi. 10.1067/mcp.2001.115455
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 1, p. 108, doi. 10.1111/bcp.12941
- By:
- Publication type:
- Article
Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 1, p. 118, doi. 10.1111/bcp.12914
- By:
- Publication type:
- Article
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 518, doi. 10.1007/s10637-014-0064-y
- By:
- Publication type:
- Article
DNA synthesis and applications to molecular biology.
- Published in:
- Medicinal Research Reviews, 1986, v. 6, n. 2, p. 135, doi. 10.1002/med.2610060202
- By:
- Publication type:
- Article
Discovery and Model‐Informed Drug Development of a Controlled‐Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 2, p. 460, doi. 10.1002/cpt.3311
- By:
- Publication type:
- Article
Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 2, p. 282, doi. 10.1002/cpt.3245
- By:
- Publication type:
- Article
Industrial Perspective on the Benefits Realized From the FDA's Model‐Informed Drug Development Paired Meeting Pilot Program.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 5, p. 1172, doi. 10.1002/cpt.2265
- By:
- Publication type:
- Article
Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 10, p. 1245, doi. 10.1002/psp4.12692
- By:
- Publication type:
- Article
Interferon Beta Assessment in Non-Chinese and Chinese Subjects: Pharmacokinetics and Pharmacodynamic Activity of an Endogenous Cytokine Are Not Race Dependent.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 10, p. 1153, doi. 10.1002/jcph.311
- By:
- Publication type:
- Article
Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2018, v. 45, n. 4, p. 649, doi. 10.1007/s10928-018-9596-7
- By:
- Publication type:
- Article
Accelerating drug development: methodology to support first‐in‐man pharmacokinetic studies by the use of drug candidate microdosing.
- Published in:
- Drug Development Research, 2007, v. 68, n. 1, p. 14, doi. 10.1002/ddr.20160
- By:
- Publication type:
- Article
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 12, p. 1755, doi. 10.1007/s40262-023-01317-4
- By:
- Publication type:
- Article
ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 12, p. 1480, doi. 10.1002/jcph.2095
- By:
- Publication type:
- Article
A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 6, p. 1063, doi. 10.1111/cts.13512
- By:
- Publication type:
- Article
Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 4, p. 1464, doi. 10.1111/cts.13008
- By:
- Publication type:
- Article
Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 3, p. 815, doi. 10.1007/s40120-023-00459-8
- By:
- Publication type:
- Article
The rate of dasotraline brain entry is slow following intravenous administration.
- Published in:
- Psychopharmacology, 2020, v. 237, n. 11, p. 3435, doi. 10.1007/s00213-020-05623-8
- By:
- Publication type:
- Article
Acute Lymphoid and Gastrointestinal Toxicity Induced by Selective p38α Map Kinase and Map Kinase-Activated Protein Kinase-2 (MK2) Inhibitors in the Dog.
- Published in:
- Toxicologic Pathology, 2010, v. 38, n. 4, p. 606, doi. 10.1177/0192623310367807
- By:
- Publication type:
- Article